Navigation Links
ABACHEM: Reliable Development and Manufacturing Service Provider
Date:5/9/2013

SHANGHAI, May 9, 2013 /PRNewswire/ -- ABACHEM is a public listed company in China, specializing in contract manufacturing to the pharmaceutical, biotechnological and agrochemical industries. Offering a broad spectrum of services for the production of fine chemicals, advanced intermediates and active pharmaceutical ingredients, we have successfully collaborated and partnered with major pharmaceutical and agrochemical companies globally. ABACHEM has also become a reliable development and manufacturing service provider and meets clients' outsourcing needs by offering cost-effective and time-efficient services and products.

Our R&D department has over 80 scientists with solid industrial experience, providing process research and development services including process selection, optimization, and verification as well as reference standard and impurity preparations. Our laboratory is fully-equipped with modern analytical instruments such as NMR, HPLC, UPLC, LC-MS and GC-MS to ensure that all projects are delivered with accuracy and a high degree of purity. DSC and ARSST are applied to every project in our lab to provide a process safety and hazard assessment. Our four kilo-labs ensure that all kilo-projects are delivered on time. An isolated and state-of-the-art kilo-lab was recently built and dedicated to cGMP projects.

ABACHEM promotes innovation and is open-minded to new ideas and technologies. For example, we recognize that heterocyclic chemistry and asymmetric synthesis are the two most complex and intriguing branches of organic chemistry. The development of technologies and processes for heterocyclic and asymmetric synthesis have been areas of long-term focus for the company. Heterocycles manufactured based on processes developed in-house, such as pyrazoles, triazoles, aza-indoles and unnatural amino acids, are some of the highlights. For chiral technology, besides the traditional asymmetric synthesis, we have recently enhanced our capability by establishing a biocatalysis group.

ABACHEM has tremendous manufacturing capability and capacity. Five of our multi-functional pilot plants ensure a smooth tech-transfer from lab to commercial scale manufacturing. In addition, through years of CMO business, the company has accumulated invaluable knowledge and experience in bulk hazardous material sourcing and handling as well as regulatory filing including the latest New Chemicals Substance filing. We also have had a good track record of persistent improvement of cost structure for our clients' commercial products.

ABACHEM is continuously and actively improving its capabilities and capacity through new technologies & engineering as well as expansions for our core CMO services. We have recently expanded our hydrogenation capacity significantly by the installation of an additional eighteen hydrogenation reactors ranging from 1000 to 5000 L with two 1000L Hastelloy reactors to provide excellent material compatibility.

About ABACHEM

Founded in 2003, ABACHEM has developed into a public company with about 400 employees and over 1.2 million square feet of laboratory and manufacturing space. Currently, the company is headquartered in Shanghai with a R&D center in Zhangjiang Hi-Tech Park of Shanghai and three manufacturing facilities in Jiangsu province which are all within driving distance to Shanghai. 

Contact:

Jane Wang
janewang@abachem.com
+86-136-6184-2021


'/>"/>
SOURCE ABACHEM
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Defeat Diabetes Foundation Teams with CoreMedica Laboratories to Provide Affordable and Reliable A1C Testing for Diabetics
2. Varian Medical Systems to Showcase Fast, Reliable, Wireless X-ray Image Detectors at the ECR Annual Meeting in Vienna Next Week
3. Fuisz Pharma Announces Patent Allowance For New Tablet And Caplet Shapes That Promote Rapid, Reliable Esophageal Transit
4. JDRF and BD Collaborate to Develop More Accurate and Reliable Glucose Monitoring Devices for People with Type 1 Diabetes
5. Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure
6. Tribogenics Expands X-Ray Development Team With Key Hires
7. FEEL Golf Co., Inc. Signs EMR Software Development Agreement with ScheduleMorePatients LLC
8. Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
9. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
10. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
11. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017  Genesis Healthcare Services has merged with Hospice ... by Bill Monast , President and CEO of ... Nathan Feltman , executives with Home Health Depot, Inc., ... This acquisition helps Hospice Cloud maintain its ... durable medical equipment (DME) solutions for the hospice industry. ...
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price ... in the global Fibromyalgia market. The research answers the ... marketed for Fibromyalgia and their clinical attributes? How are they positioned ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO ... year. Dyer started as the Chairman of the Management Committee when IFN was ... corporation including the recruitment of investor/owners and development of the business plan. He ...
(Date:2/24/2017)... CA (PRWEB) , ... February 24, 2017 , ... ... for qualifying into the Senior International Elite division on February 12th. Ms. ... Around divisions at the elite qualifier competition held in Las Vegas, Nevada. Frida ...
(Date:2/23/2017)... ... February 23, 2017 , ... On February ... a letter to withdraw previous guidance issued by the Obama Administration ... guidance issued in May 2016 by the Obama Administration came in response to ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... media outlet with a clinician-based audience, will be participating in Rare Disease Day ... in Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and ...
(Date:2/23/2017)... ... , ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North ... month of February, patients who visit Hamlin Dental Group will receive a ticket for ... at the Cheesecake Factory. , Tickets are available for routine dental visits and ...
Breaking Medicine News(10 mins):